Physician profile
David L Byrd
NPI 1447262449
$6,588.85
in general payments reported to CMS, 2019-2025
53 companies · $73.23 in 2025
The $73.23 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $1,050 · 2021: $1,513 · 2022: $1,800 · 2023: $979 · 2024: $319 · 2025: $73.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,371.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $837.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $826.91 | 2019-2024 | Farxiga, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $701.10 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $582.23 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $446.34 | 2019-2022 | |
| Pfizer INC. | $358.32 | 2019-2024 | |
| Amgen INC. | $331.53 | 2019-2025 | Repatha, Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $204.71 | 2019-2022 | |
| Lilly USA, LLC | $198.62 | 2019-2024 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.41 | 2020-2023 | Trulance, Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $157.74 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $147.39 | 2019-2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $116.81 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $103.87 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $94.91 | 2019-2023 | Eliquis |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.